论文部分内容阅读
目的:评价头孢哌酮/舒巴坦对儿童肺炎克雷伯杆菌肺炎的治疗效果。方法:选取2015年1月至2016年8月我院收治的肺炎克雷伯杆菌肺炎患儿36例,随机分为研究组和对照组各18例,对照组单用庆大霉素,研究组联合应用庆大霉素和头孢哌酮/舒巴坦,疗程均为14d,观察并记录两组患儿治疗后的临床表现、影像学表现、实验室检查、细菌学疗效和不良反应。结果:研究组临床有效率为78%,不良反应发生率为5.6%,对照组临床有效率为44%,不良发应发生率为11.1%,两组临床有效率有统计学差异(P<0.05)。结论:头孢哌酮/舒巴坦治疗儿童肺炎克雷伯杆菌肺炎疗效好,安全性高。“,”Objective: To evaluate the efficacy of cefoperazone / sulbactam in the treatment of children with Klebsiella pneumoniae pneumonia. Methods:Thirty - six patients with pneumonia of Klebsiel a pneumoniae were enrol ed in our hospital from January, 2015 to August, 2016. 18 patients were randomly divided into study group and control group. Cefoperazone / sulbactam 40 ~ 80mg / Kg, two intravenous infusion, a course of 14d; the control group in addition to cefoperazone / sulbactam, the other treatment methods are the same with the study group. The clinical manifestations, imaging findings, laboratory tests, bacteriological efficacy and adverse reactions were observed and recorded before and 14 days after treatment. Results: The clinical effective rate was 78%, the adverse reaction rate was 5.6%, the clinical effective rate was 44% in the control group and the incidence rate of adverse reactions was 11.1%. There was significant difference between the two groups (P <0.05 ). Conclusion: Cefoperazone / sulbactam is effective and safe in the treatment of Klebsiel a pneumoniae pneumonia in children.